**Supplementary Table 2. Descriptive statistics of clinical, laboratory, and fibrosis score parameters in chronic liver disease patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variables | Mean | + SD | Minimum | Maximum |
| Age (years) | 55.50 | 13.32 | 33.00 | 70.00 |
| BMI (kg/m2) | 27.33 | 2.97 | 21.30 | 32.00 |
| TLC (×109/L) | 8.16 | 3.79 | 3.50 | 14.00 |
| Hb (g/dL) | 10.95 | 1.63 | 8.90 | 15.00 |
| Platelets (×10³/µL) | 161.80 | 107.68 | 46.00 | 351.00 |
| Creatinine (mg/dL) | 1.36 | .92 | .50 | 3.60 |
| Total bilirubin (mg/dL) | 3.01 | 2.63 | .50 | 7.80 |
| Direct bilirubin (mg/dL) | 1.53 | 1.37 | .20 | 4.10 |
| AST (IU/L) | 49.10 | 23.16 | 13.00 | 87.00 |
| ALT (IU/L) | 32.00 | 32.54 | 13.00 | 127.00 |
| INR | 1.36 | .18 | 1.00 | 1.60 |
| Albumin (g/dL) | 3.07 | .40 | 2.40 | 3.50 |
| AFP (ng/mL) | 4.53 | 2.38 | 1.60 | 9.00 |
| ALBI score | -1.60 | .45 | -2.31 | -.64 |
| CRP (mg/L) | 8.50 | 11.64 | .50 | 39.00 |
| NLR | 8.40 | 5.25 | 2.00 | 18.00 |
| PLR | 210.07 | 118.50 | 47.50 | 420.00 |
| AST/ALT ratio | 2.17 | 1.70 | .64 | 6.69 |
| FIB 4 | 4.85 | 3.16 | .68 | 10.22 |
| APRI | 1.13 | .82 | .10 | 3.10 |
| NFS | 1.52 | 2.85 | -3.23 | 6.42 |
| circRNA value | 5.52 | 2.49 | 2.47 | 9.83 |
| MELD | 15.80 | 4.14 | 10.00 | 24.00 |
| MELD NA | 19.80 | 7.04 | 10.00 | 30.00 |

AFP, alpha-feto protein; ALBI, Albumin-Bilirubin score; ALT, alanine aminotransferase; APRI, Aspartate Aminotransferase to Platelet Ratio Index; AST, Aspartate Aminotransferase; BMI, body mass index; circRNA, circular RNA; CRP, C. reactive protein; FIB-4, Fibrosis-4; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; MELDNA, Model for End-Stage Liver Disease-Na; NFS, NAFLD Fibrosis Score; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SD, standard deviation; TLC, total leucocytic count.